In September 2025, the utility-scale solar construction subsidiary of Quanta Services — a company called Blattner that operates as one of the largest engineering-procurement-construction (EPC) contractors in U.S. renewable energy infrastructure — announced it was deploying dozens of autonomous solar pile-driving robots built by a San Francisco-based construction-robotics startup called Built Robotics on the company’s nationwide solar installation projects. The robots in question are not new platforms purpose-built for autonomy. They are conventional hydraulic excavators — the same Caterpillar, Komatsu, Volvo, and Hitachi excavators that have been operating on construction sites since the mid-twentieth century — retrofitted with Built Robotics’ Exosystem, an aftermarket autonomy upgrade kit that converts a manually-operated excavator into a fully-autonomous robot in approximately four hours of installation time and that, critically, remains fully reversible. The Exosystem sits below the excavator’s boom mobilization height, so the machine remains transportable. The system includes six 360-degree onboard cameras, RTK GPS positioning accurate to centimeters, IMU-based kinematic software, an all-weather ruggedized enclosure, and a liquid-cooled embedded computing platform. The robot operates 24 hours a day on solar pile-driving projects, requires only periodic resupply and refueling, and has demonstrated production rates of approximately 2.5 times the equivalent human-operated baseline. Built Robotics CEO Noah Ready-Campbell — the former Google engineer who founded the company in 2016 and who has, over the intervening decade, become one of the most identifiable figures in U.S. construction robotics — publicly framed the deployment thesis around 24/7 operation enabling project schedule acceleration in a way that conventional construction crews structurally cannot.

The Built Robotics-Blattner partnership is the cleanest single illustration of the structural argument that has, over the past decade, finally begun to unlock construction robotics as a commercial category: construction does not automate the way warehouse logistics, factory manufacturing, or hospital operations automate. Construction sites are heterogeneous by definition — every project has different terrain, different blueprints, different weather, different crews, different supply chains, different regulatory environments, different existing infrastructure to work around. The general-purpose humanoid robot that operates inside a structured Mercedes-Benz factory floor or an Amazon fulfillment center cannot, in any practical 2026 sense, walk onto a residential construction site and frame a house. The category that has succeeded in construction is the category that picked a single repetitive task — pile driving, drywall installation, layout marking, brick laying, demolition, site survey — automated that one task at scale, and let humans handle everything else. The successful construction-robotics platforms are not general-purpose. They are surgically specialized.

Why construction is the last major industry to automate

The fundamental productivity statistic that defines the construction-robotics market opportunity is the McKinsey Global Institute analysis showing that U.S. construction productivity has been approximately flat over the past 50 years, while manufacturing productivity has grown by approximately seven times over the same period. Construction is, by every available labor-productivity measure, the largest U.S. industry that has not meaningfully been transformed by automation. The structural reasons are well-documented. Construction projects are bespoke. Construction sites are outdoor, weather-exposed, and physically chaotic. Construction crews are heterogeneous — the same project can involve dozens of subcontractors from different trades, each operating on different schedules and with different equipment. The regulatory environment is fragmented across federal, state, and municipal jurisdictions. The supply chain is project-specific. The skilled labor pool is, in 2024-2026 terms, severely undersupplied — the Associated General Contractors of America estimated U.S. construction needed approximately 500,000 additional workers in 2024 above existing employment to meet demand, with the underlying skilled-trades training pipeline producing replacement workers at substantially lower rates than the construction-industry retirement and turnover curve requires, and with the underlying labor shortage projected to persist through the late 2020s. These structural conditions are simultaneously the reason construction has not been automated historically and the reason automation has, in the 2020s, finally become economically viable. The labor cost is rising fast enough, and the project-volume demand is large enough, that the return-on-investment math has shifted in favor of specialized robotic platforms in a way it has not previously supported.

The single largest demand-side driver of construction-robotics investment in the 2020s has been federal infrastructure spending. The Infrastructure Investment and Jobs Act (IIJA) signed in November 2021 authorized approximately $1.2 trillion in federal infrastructure spending across roads, bridges, public transit, broadband, water systems, and electric grid upgrades. The Inflation Reduction Act (IRA) signed in August 2022 authorized approximately $369 billion in clean energy and climate-related spending, including the solar tax credits and renewable-energy investment incentives that have driven the utility-scale solar construction boom Built Robotics is now servicing. These two pieces of legislation, in combined dollar volume, represent the largest peacetime federal infrastructure capital deployment in U.S. history, and they have created the multi-year construction-demand environment that has made specialized robotic platforms economically defensible at unit-deployment scale.

The 3D-printed residential construction story: ICON, Wolf Ranch, and the Lennar deployment

The most operationally consequential 3D-printing construction company in the United States is ICON, an Austin, Texas-based construction technology company that operates the Vulcan robotic construction system. The Vulcan printer is, in physical terms, an approximately 46.6-foot-wide by 15.6-foot-tall robotic gantry that extrudes a proprietary cement-based material called Lavacrete through a nozzle in successive horizontal layers, building the walls of a single-family home in approximately three weeks of printing time per unit, with the foundation and metal roof installed using conventional construction methods. ICON’s flagship deployment is the Wolf Ranch community in Georgetown, Texas — a 100-home master-planned development north of Austin, built in partnership with national homebuilder Lennar Corporation (NYSE:LEN) and co-designed by Danish architectural firm BIG-Bjarke Ingels Group. The Wolf Ranch homes range from 1,500 to 2,100 square feet, with three to four bedrooms, and were priced starting in the mid-$400,000s at the project’s initial sales launch in 2023. The development is part of Hillwood Communities, a Perot Company. As of August 2024, more than 80 percent of the Genesis Collection homes had sold, with the first homeowners moving in beginning September 2023. The Wolf Ranch project is, in 2026 operational terms, the largest 3D-printed residential community ever completed anywhere in the world.

ICON’s broader portfolio extends beyond Wolf Ranch. The company has partnered with the Texas Military Department on 3D-printed military barracks construction. The company built the first 3D-printed homes for Habitat for Humanity in Williamson County, Texas. ICON has additional 3D-printing deployments in El Cosmico, the BIG-co-designed glamping resort expansion in Marfa, Texas, with home prices reaching into the seven figures for the larger custom units. The company’s Vulcan printer is a multi-million-dollar piece of capital equipment that requires specialized operators, customized proprietary materials, and ongoing engineering support. The 3D-printing residential construction category in 2026 is, in industry-wide terms, still small — ICON, Apis Cor, COBOD International (the Danish manufacturer that supplies Vulcan-style construction printers to international markets), and a handful of smaller specialist competitors collectively account for low-four-figure units of completed 3D-printed housing globally — but the category is growing at the highest rate of any subcategory in residential construction technology.

The autonomous heavy equipment category: Caterpillar Command, Komatsu Smart Construction, and the Built Robotics retrofit thesis

The largest single category of construction robotics by deployed unit count is autonomous heavy equipment, dominated by the major incumbent manufacturers — Caterpillar, Komatsu, Volvo Construction Equipment, Hitachi Construction Machinery, and Chinese manufacturer Sany. Caterpillar’s Command for hauling autonomous truck system has been operationally deployed across multiple large-scale mining operations since 2013, with more than 500 autonomous haul trucks operating across BHP, Rio Tinto, Fortescue, and Suncor mining sites globally as of 2024. Komatsu operates the Smart Construction platform, which integrates autonomous bulldozer operation, drone-based site survey, and BIM-driven excavation planning into a single integrated workflow. Volvo CE has demonstrated the TARA autonomous hauler. The autonomous heavy equipment category, when measured by total deployed-unit count, dwarfs every other construction-robotics category — but the deployed units are heavily concentrated in mining, aggregates, and large-scale resource extraction rather than in conventional building construction, where site heterogeneity makes autonomous-equipment deployment substantially harder.

The Built Robotics thesis — retrofit aftermarket autonomy onto existing fleets of conventional excavators rather than selling purpose-built autonomous platforms — represents a different commercial bet. The Exosystem retrofit kit can be installed on mid-size excavators from any of the major manufacturers, the installation is reversible, and the business model bills as a combined monthly rental fee plus hourly operation wage rather than a large upfront capital purchase. The company’s pivot from general construction trenching to solar farm pile driving, announced in 2023 and consummated through the Blattner partnership in 2025, reflects the structural lesson that has emerged across construction robotics: the path to commercial scale runs through specialized, repetitive, high-volume applications rather than through general-purpose automation. Built Robotics’ RPD 35 autonomous pile-driving platform is the operational expression of this thesis. The platform was granted a U.S. patent for the autonomous pile-driving system in February 2025. The deployment focus is on U.S. and Australian solar markets through 2026.

The specialized indoor-construction robots: Dusty Robotics, Canvas, Hadrian X, and Hilti Jaibot

The indoor-construction specialty-robot category includes a growing number of platforms each focused on a single repetitive task. Dusty Robotics, the Mountain View-based construction-robotics company founded in 2018 by Tessa Lau and Philipp Herzig, builds the FieldPrinter — a small, wheeled, ground-printing robot that automatically marks construction layouts on concrete slabs from BIM model data. The platform replaces the manual chalk-line and tape-measure layout process that has, for decades, been one of the most labor-intensive and error-prone steps in commercial construction, with FieldPrinter deployments documented across major U.S. general contractors including DPR Construction and Suffolk. Canvas, the San Francisco-based drywall-finishing robotics company founded in 2017, builds an autonomous platform that applies and finishes drywall joint compound — taping, mudding, and sanding — using a robotic arm mounted on a mobile base, with the platform’s first commercial deployments concentrated in Bay Area commercial construction projects. Fastbrick Robotics, the Australian company that builds the Hadrian X automated brick-laying robot, operates a truck-mounted articulated boom that places bricks at a documented rate of approximately 200 bricks per hour, in continuous operation, with the first commercial home deployments completed in Western Australia and the platform being expanded into the U.S. and Mexican markets through partnerships with Wienerberger and other major brick producers. Hilti, the Liechtenstein-based construction tool manufacturer, operates the Jaibot — a semi-autonomous overhead drilling robot designed for the high-volume drilling required in mechanical, electrical, and plumbing (MEP) ceiling installations in commercial construction, marketed as a way to reduce the repetitive overhead labor that contributes disproportionately to construction-trade musculoskeletal injuries.

The demolition robot category: Brokk and Husqvarna

The demolition robotics subcategory operates with a different operational logic than the rest of construction robotics. Demolition robots are remote-operated rather than autonomous. They are designed primarily to remove humans from environments where structural collapse, asbestos exposure, or radiological contamination would make manual demolition unacceptably dangerous. The category leader is Brokk, the Skellefteå, Sweden-based manufacturer that has, since 1976, produced compact electric-and-hydraulic demolition robots ranging from the Brokk 70 (170 kilograms, designed for tight indoor spaces) through the Brokk 900 (10,500 kilograms, designed for large-scale industrial demolition). Brokk robots have been deployed in nuclear decommissioning at Sellafield in the United Kingdom, at Fukushima Daiichi in the post-2011 reactor stabilization operation, and across major infrastructure renovation projects globally. Husqvarna, the Swedish power equipment manufacturer, builds the competing DXR demolition robot line. The demolition robot category is, in commercial terms, smaller than autonomous-heavy-equipment or specialty-indoor-robot categories — but the platforms operate in environments where the alternative to robotic deployment is either prohibitive worker risk or non-completion of the project.

The site-monitoring robot category: Boston Dynamics Spot at Skanska, Suffolk, and the general-contractor wave

The site-monitoring robotics subcategory has, since approximately 2020, been dominated by Boston Dynamics’ Spot quadruped platform deployed by major general contractors for daily site documentation, BIM-comparison verification, safety inspection, and progress tracking. Spot deployments at major U.S. and international general contractors include Skanska, Suffolk Construction, Brasfield & Gorrie, Pomerleau in Canada, Foster + Partners‘s construction documentation operations, and the Pomerleau-Built Robotics consortium that has piloted combined autonomous-equipment-plus-site-monitoring workflows. Spot’s site-monitoring deployment typically involves a robot equipped with a 360-degree camera and laser scanner walking a pre-programmed route through an active construction site at regular intervals — typically daily — capturing high-resolution imagery and point-cloud data that is then processed against the project’s BIM model to identify construction deviations, safety violations, and progress milestones. The structural value proposition is data continuity: a human inspector visits a site weekly, while a Spot deployment generates daily documentation, producing a temporal density of project-state data that no human inspection process can match.

The reality-capture software category that processes Spot’s output and competing aerial drone imagery is dominated by OpenSpace, HoloBuilder (acquired by FARO Technologies in 2021), DroneDeploy, and Procore Technologies (NYSE:PCOR). These platforms transform raw drone, robot, and 360-camera imagery into spatially-indexed, BIM-aligned, time-series construction documentation that has become standard practice across major general contractors in the United States.

The drone surveying and aerial photogrammetry category

The construction-site drone category, separate from the indoor-robot category, is dominated by DJI — the Shenzhen-based drone manufacturer that has, despite the ongoing U.S. federal procurement restrictions and the broader scrutiny of Chinese commercial drone technology, continued to operate as the de facto standard for commercial construction site surveying. The DJI Phantom 4 RTK and Matrice 350 RTK platforms operate across U.S. commercial construction sites in volumes that no other manufacturer approaches, with the platforms typically deployed for weekly photogrammetric site surveys, monthly volumetric calculations of aggregate stockpiles, quarterly progress documentation, and incident-specific aerial documentation when safety or quality issues require it. Skydio, the San Mateo-based autonomous-drone manufacturer that has positioned itself as the U.S.-government-approved alternative to DJI, has captured share in federally-funded construction projects and infrastructure inspection deployments. Parrot Anafi USA, the federal-compliant drone built by French manufacturer Parrot, operates in the same federal-procurement segment. Wingtra, the Swiss fixed-wing survey drone manufacturer, operates in the larger-area aerial photogrammetry segment where multirotor drone endurance becomes constraining. AgEagle and Sentera operate adjacent platforms primarily marketed for agricultural and land-management surveying but used in some construction-site applications.

The Katerra collapse and the prefab modular construction cautionary tale

The construction-technology category is not without its operational casualties, and the largest single failure in the recent history of construction robotics and prefabrication is the Katerra collapse. Katerra was founded in 2015 by Michael Marks (the former Flextronics CEO), Fritz Wolff, and Jim Davidson, with the thesis that construction could be transformed by applying manufacturing-industry vertical-integration logic to residential and commercial building production. The company raised more than $2 billion in venture capital, including a $865 million round led by SoftBank Vision Fund in 2018. Katerra acquired multiple architectural firms, engineering firms, and prefabrication factories. The company filed for Chapter 11 bankruptcy in June 2021 after, by available reporting, burning through the bulk of its capital on factory buildouts that never achieved sustainable unit-economics. The Katerra collapse is the clearest single counterexample to the thesis that construction can be straightforwardly automated by importing factory-manufacturing logic into the construction process. The successful 2020s construction-robotics companies — Built Robotics, Dusty, Canvas, ICON, Hadrian X — have all taken a different operational approach. They have not tried to vertically integrate the construction industry. They have taken individual repetitive tasks and automated them in isolation, leaving the rest of the construction value chain unchanged.

What 2026 looks like across construction robotics and drones

In 2026, the construction-robotics category is structurally distributed across a small number of operationally dominant platforms in each subcategory. Autonomous heavy equipment is dominated by the major incumbent manufacturers (Caterpillar Command, Komatsu Smart Construction, Volvo CE TARA) operating primarily in mining and aggregates, with Built Robotics’ Exosystem retrofit platform operating in the specialized solar pile-driving application. 3D-printed residential construction is dominated by ICON’s Vulcan platform, with the Wolf Ranch deployment as the operational proof point and Apis Cor, COBOD, and smaller specialists competing in the broader global market. Indoor specialty robots are dominated by Dusty FieldPrinter (BIM-driven layout marking), Canvas (drywall finishing), Hadrian X (brick laying), and Hilti Jaibot (overhead MEP drilling). Demolition is dominated by Brokk and Husqvarna DXR. Site monitoring is dominated by Boston Dynamics Spot at major general contractors, with OpenSpace, HoloBuilder (FARO), and DroneDeploy as the reality-capture software layer. Aerial surveying is dominated by DJI Phantom 4 RTK and Matrice 350 RTK, with Skydio and Parrot capturing the federal-procurement-restricted segment. The underlying market is, by industry analyst estimates, approximately $4-6 billion annually in 2026 across all construction-robotics subcategories combined, with double-digit annual growth driven by the IIJA and IRA infrastructure spending wave and the persistent construction labor shortage.

The structural story across construction robotics in 2026 is the opposite of the structural story in factory humanoid robotics. The factory humanoid thesis — most aggressively expressed by Tesla Optimus, Figure 02, Apptronik Apollo, and Agility Digit — is that a general-purpose bipedal platform will eventually be flexible enough to perform any task in a structured factory environment, replacing human labor on a task-substitution basis. The construction robotics thesis is the inverse. The successful construction-robotics platforms have all converged on the observation that construction sites are too heterogeneous, too weather-exposed, too physically chaotic, and too project-specific for a general-purpose platform to operate reliably. The path to commercial success runs through hyper-specialization. Build a robot that does pile driving. Build a robot that does drywall. Build a robot that does brick laying. Build a robot that does layout printing. Do not build a robot that does construction generally, because construction generally is the most heterogeneous physical operation in the modern economy and no single platform is going to do all of it.

The deployed-robot fleets that exist in 2026 reflect this convergence. There is no humanoid robot operating on a U.S. construction site in any commercially-significant volume. The Tesla Optimus, Figure, and Apptronik platforms that have accumulated thousands of deployment hours in Mercedes-Benz, BMW, and GXO Logistics facilities have, as of public disclosure, zero deployment hours on conventional construction sites. The Boston Dynamics Atlas humanoid that has accumulated extensive public demonstration footage of parkour and gymnastic movements has not, in any documented commercial sense, been deployed for construction work. The construction-robotics platforms that operate at meaningful commercial scale are wheeled, tracked, or articulated industrial machines that have been retrofitted or purpose-built for a single specialized task. The form factor that has succeeded in this category is, structurally and operationally, the form factor that pre-existed humanoid robotics — the heavy equipment chassis, the gantry printer, the wheeled mobile base, the truck-mounted articulated boom — augmented with the autonomy, computer vision, and embedded computing capability that has emerged across the broader industrial robotics economy in the 2020s.

The question that defines the next decade of construction robotics is whether this hyper-specialized convergence will continue, or whether the general-purpose humanoid platforms will eventually become reliable enough, mobile enough, and weather-resistant enough to operate on construction sites at all. The available evidence in 2026 is that the hyper-specialized convergence will continue. Construction sites are not Mercedes factories. They are not Amazon warehouses. They are not hospital corridors or fulfillment centers or any other operationally-structured environment where a humanoid platform can be trained to perform routine tasks. Construction sites are improvised, weather-exposed, multi-trade environments where the only operating logic that has, over the past decade of attempted automation, actually worked is the logic of automating one repetitive task at a time and leaving everything else to the human workforce, in direct contrast to the generalist deployment thesis driving the commercial humanoid robotics industry.

The Built Robotics-Blattner solar pile-driving partnership is, in 2026 operational terms, the cleanest illustration of what successful construction robotics looks like. A specialized robotic platform automating a single repetitive task — driving steel piles into the ground for solar array foundations — at a 2.5x productivity multiplier over manual operation, 24 hours a day, across an enormous addressable market created by the federal renewable-energy spending wave. The robot doesn’t try to do anything else. It doesn’t have to. The construction industry, after fifty years of frustrated automation attempts, has finally figured out that the way to put robots on construction sites is to put them on construction sites one task at a time. The robots that work are the robots that do less, more reliably, in the specific operational niche where their physical constraints align with the project’s repetitive labor demands. The pipeline of federal infrastructure spending and the persistent construction labor shortage have, between them, created the demand environment that finally makes specialized construction robotics economically defensible. The 2026 operational reality is that the construction industry is being automated, but not the way the general-purpose humanoid evangelists predicted. It is being automated the way the heavy-equipment industry was always going to automate — task by task, machine by machine, retrofit by retrofit, with humans doing what humans do best and robots doing what robots do best, on construction sites that have, after a half-century of resistance, finally become economically viable to put robots on.

In October 2025, a Los Angeles-based sidewalk delivery robotics company called Serve Robotics — the publicly-traded Uber-and-NVIDIA-backed autonomous-delivery operator that spun out of Postmates in 2017, continued under Uber after the Postmates acquisition, separated as an independent company in 2021, and went public via a reverse merger in April 2024 under the ticker NASDAQ:SERV — announced it was acquiring Diligent Robotics, the Austin-based hospital logistics robotics company founded in 2017 by Dr. Andrea Thomaz and Dr. Vivian Chu, the developers of the Moxi mobile manipulation robot that has, over the eight intervening years, become the most operationally consequential autonomous robot deployed inside U.S. hospitals. The acquisition valued Diligent’s common stock at $29 million, against the more than $75 million Diligent had raised in venture capital across its lifecycle. The strategic logic was articulated publicly by Serve’s leadership: the Moxi platform was operating across more than 25 U.S. hospitals, had completed more than 1.25 million deliveries of medications, lab samples, and supplies in real hospital corridors, and represented one of the largest deployed fleets of NVIDIA-powered mobile manipulator robots in any commercial healthcare context. Each hospital deployment was projected to generate $200,000 to $400,000 annually in recurring revenue. The data set — eight years of autonomous mobile robot navigation in unstructured, dynamic, human-crowded indoor environments — was the asset Serve’s leadership identified as the most valuable component of the transaction.

The Serve-Diligent deal is the cleanest 2026 illustration of the structural argument that defines the healthcare operations robotics category: the most valuable real-world mobile manipulation data on Earth is being generated inside hospital corridors, where robots operate alongside nurses, pharmacy staff, and supply technicians performing the routine logistics tasks that consume an estimated 30 percent of a clinical nurse’s working time and that are, as the modern hospital labor shortage has converged with the maturity of mobile manipulation hardware, the single largest addressable market for non-patient-care robotics in the healthcare economy. The robots in this category do not diagnose. They do not perform surgery. They do not deliver medication to a patient’s bedside in a clinical sense. They do not function as direct caregivers in the way the patient-facing healthcare robotics industry does. They move pills from a centralized pharmacy to a nursing station. They carry blood samples from a patient floor to the laboratory. They restock supply cabinets overnight. They sterilize empty patient rooms between admissions. They compound chemotherapy infusions in IV-mixing isolators that operate without exposing human pharmacy technicians to cytotoxic agents. They deliver prescriptions from a hospital pharmacy to a patient’s home via autonomous drone. They are the back-of-house infrastructure layer that makes the modern hospital function, and they are, in 2026, the most rapidly scaling category in the entire healthcare robotics industry.

The Moxi industrial story and the NVIDIA mobile-manipulation stack

The Moxi platform is, in mechanical terms, a 4-foot-8-inch wheeled mobile robot with a single articulated arm, a cartoon-like animated face on a small upper-body display, and a payload cabinet that can be configured for medication delivery, lab sample transport, supply restocking, or linen distribution. The robot was designed deliberately with a non-threatening, non-humanoid visual identity — the cartoon face, the slow conservative movement profile, the visible eye-blink animation — to maximize acceptance by clinical staff who would be sharing corridors with the platform on every shift. Andrea Thomaz, the company’s CEO and a former University of Texas at Austin computer science professor whose academic work centered on socially assistive robotics, articulated the design thesis publicly: Moxi is engineered to be perceived by hospital staff as a colleague, not as a tool, on the empirical evidence that staff adoption is the primary determinant of whether a back-of-house hospital robot generates the productivity gains its return-on-investment case depends on.

Moxi 2.0, unveiled on October 28, 2025 — approximately the same week as the Serve Robotics acquisition — runs on NVIDIA’s IGX Thor, the Blackwell-architecture industrial-grade embedded computing platform that NVIDIA positioned in 2024-2025 as the reference compute substrate for safety-critical autonomous mobile manipulation. The platform pairs NVIDIA’s edge AI compute with Diligent’s proprietary AI foundation model, trained on the three years of proprietary data Moxi has accumulated across its hospital deployments. The 1.25 million deliveries figure, in operational terms, represents one of the largest single-purpose deployed-robot data sets in commercial use anywhere in the world — larger than the publicly-disclosed deployment-data sets that Tesla, Figure, Apptronik, Boston Dynamics, and Agility Robotics have disclosed for their factory-floor humanoid platforms combined. Diligent’s stated objective is to double its hospital footprint annually and deploy thousands of Moxi units by 2030, with platform improvements designed to support rollouts of more than 15 units per site at the larger hospital systems.

The Aethon TUG genealogy and the older mobile-robot platform

The Moxi platform did not invent the hospital mobile delivery robot category. The category was pioneered by Aethon, a Pittsburgh-based mobile robotics company founded in 2001 that built the TUG autonomous mobile robot — a flat-platform wheeled robot designed to tow carts of medications, linen, food trays, or surgical instruments through hospital corridors using a combination of laser scanning, pre-mapped facility floor plans, and centralized fleet management software. Aethon was acquired by ST Engineering (the Singapore-based defense and engineering conglomerate) in 2019 and operates as ST Engineering Aethon. The TUG platform has accumulated more than 4,000 deployed units across hospitals globally over the platform’s two-decade operational history, with installations in major academic medical centers including UCSF Medical Center, Cedars-Sinai, the Cleveland Clinic, and the Mayo Clinic. The TUG-versus-Moxi distinction is, in operational terms, the distinction between a tow-tractor logistics platform (TUG carries large carts, operates predominantly at night, and minimizes human-corridor interaction) and a mobile-manipulation social robot (Moxi operates during daytime shifts, performs single-item deliveries with arm-based manipulation, and is designed for active interaction with clinical staff). Both platforms address the same underlying labor-cost problem. They address it with different operational architectures.

The pharmacy automation market: Omnicell, Swisslog, Parata, and McKesson

The largest revenue category within healthcare operations robotics is not mobile delivery but stationary pharmacy automation — the dispensing systems, packaging machines, and inventory management robots that operate in centralized hospital pharmacies and retail pharmacy chains. The publicly-traded category leader is Omnicell, Inc. (NASDAQ:OMCL), the Mountain View, California-based pharmacy automation company that builds automated dispensing cabinets, IV compounding robots, and central pharmacy automation systems. Omnicell’s installed base includes approximately 6,000 hospital and health system customers globally, with the XT Series automated dispensing cabinets deployed across more than 50,000 hospital nursing units worldwide, providing the biometric access control and audit-trail infrastructure that DEA Schedule II controlled-substance management requires. The company’s market capitalization has fluctuated significantly in the 2023-2026 window — from peaks above $7 billion during the 2021 healthcare-automation enthusiasm to trough valuations below $1.5 billion during the 2023-2024 healthcare-IT contraction — but the underlying installed base has continued to expand even through the financial volatility.

Swisslog Healthcare, the Swiss-headquartered healthcare automation division of KUKA (which is itself owned by Chinese appliance giant Midea Group following the 2017 acquisition), operates the BoxPicker robotic pharmacy storage system and the PillPick unit-dose packaging robot, with installations across major academic medical centers including Stanford Health Care, NewYork-Presbyterian, and Geisinger Medical Center. Parata Systems, the retail-pharmacy automation specialist based in Durham, North Carolina, was acquired by Becton, Dickinson and Company (BD) in March 2022 for approximately $1.5 billion and now operates as part of BD’s pharmacy automation platform, building the Max and Mini counting-and-vialing robots that fill retail prescription bottles at independent and chain pharmacies. McKesson Corporation operates the PROmanager-Rx automated counting and dispensing platform across its pharmacy distribution network. Capsa Healthcare builds the NexsysADC automated dispensing cabinet line. Boston Dynamics‘ Stretch case-handling robot has been piloted in pharmacy distribution warehouses feeding hospital systems. The pharmacy automation market, in 2026, is estimated by industry analysts at approximately $5.5 billion in annual revenue globally, with high-single-digit annual growth driven by hospital labor cost pressure and the continued expansion of unit-dose dispensing as the standard medication administration architecture in U.S. healthcare.

The sterile compounding robots: chemotherapy automation and the ARxIUM RIVA story

The most operationally specialized robots in the healthcare operations category are the sterile compounding systems used to mix intravenous medications — particularly chemotherapy infusions — in environments where human pharmacy technicians would otherwise be exposed to cytotoxic, mutagenic, and teratogenic agents through routine compounding work. The RIVA (Robotic IV Automation) system, originally developed by Winnipeg-based Intelligent Hospital Systems and now operated by ARxIUM after the 2017 acquisition, is a fully-enclosed compounding robot that mixes chemotherapy infusions, total parenteral nutrition (TPN), and other high-risk IV medications inside a sealed sterile-class isolator using robotic arms operating on the medication vials and IV bags directly. RIVA installations have, in operational terms, demonstrated the capability to compound several hundred IV preparations per day across an eight-hour shift, with quality and dosage verification that exceeds the documented error rates of manual pharmacy compounding. The Equashield closed-system transfer device line and B. Braun’s APOTECAchemo robotic compounding platform compete in the same operational niche. The sterile compounding robotics market is, in 2026, the most safety-critical operational category in healthcare robotics — a category where the cost of automation failure is not lost productivity but acute clinical toxicity, where the regulatory framework is built around USP General Chapter 797 (sterile compounding) and USP General Chapter 800 (hazardous drug handling), and where the customer acquisition cycle is correspondingly longer and the deployed-fleet expansion correspondingly slower than in the mobile delivery or pharmacy dispensing categories.

The laboratory automation market: Hamilton, Tecan, Beckman Coulter, and the Cellares cell-therapy wave

The category that has, by every revenue and unit-deployment metric, expanded most rapidly in healthcare operations robotics over the 2020-2026 window is laboratory automation, the dedicated liquid-handling robots, sample-processing systems, and high-throughput screening platforms that automate the routine pipetting, plating, and assay operations that define both clinical diagnostic laboratories and pharmaceutical research operations. The publicly-traded category leaders include Hamilton Company, the Reno-based liquid handling specialist; Tecan Group (SIX:TECN), the Swiss laboratory robotics manufacturer with major U.S. operations; Beckman Coulter Life Sciences, the diagnostic and research instrumentation business operated under Danaher Corporation (NYSE:DHR); and the broader Thermo Fisher Scientific (NYSE:TMO) automation portfolio. The category is dominated by stationary, dedicated robotic platforms that perform highly specialized tasks — automated microplate pipetting, automated cell-culture handling, automated PCR setup, automated immunoassay processing — at throughput levels that no human laboratory technician can match.

The most rapidly-growing subcategory within laboratory automation is cell therapy manufacturing automation, the dedicated robotic platforms that automate the production of patient-specific cell therapies (CAR-T cancer treatments, induced pluripotent stem cell therapies, autologous regenerative medicines). Cellares Corporation, the South San Francisco-based cell therapy manufacturing specialist, raised $255 million in Series C funding in February 2023 to deploy its Cell Shuttle automated cell therapy manufacturing platform. Multiply Labs, the South San Francisco-based pharmaceutical robotics company, builds automated production platforms for personalized medicines. Resilience (formerly National Resilience), the Andreessen Horowitz-backed biomanufacturing company, has expanded its automated cell therapy and biologics manufacturing footprint substantially over the 2023-2026 window. The cell therapy automation category exists at the intersection of pharmaceutical manufacturing, regulatory compliance, and the broader laboratory automation market, and it is the subcategory most likely to drive the next decade of capital investment in healthcare operations robotics.

The UV disinfection robotics market: Xenex, UVD Robots, and the post-COVID contraction

The healthcare operations robotics category that experienced the most dramatic boom-and-contraction cycle over the 2020-2024 window was UV-C disinfection robotics. The pandemic-era enthusiasm for autonomous hospital disinfection drove rapid deployment of platforms including Xenex LightStrike (San Antonio-based, pulsed xenon UV disinfection, with installations across more than 800 U.S. hospitals at the 2020-2021 deployment peak), UVD Robots (Odense, Denmark-based, a subsidiary of Blue Ocean Robotics, mobile UV-C disinfection platform with installations across European and U.S. hospitals), and Tru-D SmartUVC (Memphis, Tennessee-based, UV-C disinfection platform acquired by PDI Healthcare in 2022). The market hit its operational peak in 2021. The market subsequently contracted as pandemic-emergency procurement budgets normalized, as the underlying clinical evidence for autonomous UV-C disinfection’s hospital-acquired-infection reduction outcomes remained more mixed than the early enthusiasm had implied, and as competing infection-control approaches — hydrogen peroxide vapor systems, copper-impregnated surfaces, standard manual cleaning with improved compliance verification — captured share. The category, in 2026, is operationally smaller than it was in 2021, with the surviving vendors having repositioned around long-term-care facilities, outpatient surgical centers, and laboratory cleanrooms rather than the inpatient hospital deployment that defined the pandemic-era peak.

The Zipline drone delivery story and the hospital-to-home pharmacy distribution category

The most rapidly-growing aerial robotics platform in U.S. healthcare logistics is Zipline, the South San Francisco-based autonomous drone delivery company founded in 2014 by Keller Rinaudo Cliffton, Keenan Wyrobek, and Will Hetzler that originally scaled its operations in Rwanda starting in 2016 delivering blood, vaccines, and medical supplies to remote clinics. Zipline’s Platform 2 (P2) delivery system, designed for urban and suburban deployment with a fully autonomous parent drone hovering at altitude while a tethered delivery “droid” descends to deliver payloads directly to porches, patio tables, or front steps, has driven the company’s U.S. healthcare expansion since 2023. As of October 2025, Zipline has completed more than 1 million commercial deliveries globally — a figure the company publicly notes would have required 120 years of human pilot flight time. The U.S. healthcare partnerships span an expanding list of major health systems: Cleveland Clinic launched prescription drone delivery in northeast Ohio in 2025 under the leadership of Bill Peacock (Chief of Operations) and Geoff Gates (Senior Director of Supply Chain Management). Mayo Clinic is operating Zipline drone delivery for hospital-at-home patients. Memorial Hermann Health System in Houston, under the leadership of Alec King (Executive Vice President and CFO), is launching service in 2026. Michigan Medicine, Intermountain Health, MultiCare Health System, and WellSpan Health in Pennsylvania round out the major U.S. healthcare partnerships.

The P2 platform completes 10-mile trips in approximately 10 minutes, carries payloads up to 8 pounds, operates electrically with zero emissions, and operates in rain, wind, and extreme cold conditions that would otherwise slow ground delivery. The hospital-to-home pharmacy distribution use case — specialty medications, lab samples between system facilities, eventually rush prescriptions and surgical supplies — is the single most operationally novel logistics category in U.S. healthcare in 2026, with the underlying regulatory architecture (FAA Part 135 air carrier certification, BVLOS waivers) having been substantially built out over the 2022-2025 window. Matternet operates the parallel hospital-network drone delivery service in the United States with major partnerships including the Wake Forest Baptist Health-WakeMed network in North Carolina and the UPS Flight Forward consolidated drone delivery infrastructure. Wingcopter, the German-based fixed-wing eVTOL drone manufacturer, operates in the European and African medical drone delivery market.

The Vecna restructuring and the hospital logistics market contraction

The healthcare operations robotics market is not without its operational casualties. Vecna Robotics, the Massachusetts-based mobile robotics company founded in 1998 that pivoted from healthcare logistics to broader warehouse automation in the late 2010s, underwent significant layoffs and restructuring in 2024 amid the broader contraction in venture-backed warehouse robotics. The hospital logistics market, like the warehouse logistics market, has experienced the standard venture-backed-startup mortality pattern: a small number of operational leaders (Diligent, Aethon, Omnicell, Swisslog) capturing the bulk of the deployment market, with a long tail of smaller specialist companies that have either been acquired by the leaders, pivoted to adjacent markets, or contracted operations. The Serve-Diligent acquisition in October 2025 is one expression of the consolidation pressure. The BD-Parata acquisition in 2022 was an earlier expression. The ST Engineering-Aethon acquisition in 2019 was earlier still.

The labor-cost story driving everything

The fundamental economic driver behind every category in healthcare operations robotics — pharmacy automation, mobile delivery, sterile compounding, laboratory automation, UV disinfection, drone delivery — is the U.S. healthcare labor cost trajectory. Registered nurse compensation in the United States has, by Bureau of Labor Statistics data, risen from approximately $73,000 median annual wage in 2019 to approximately $94,500 median annual wage in 2024 — a 29 percent nominal increase that substantially exceeded both general wage inflation and consumer price index growth over the same period. The U.S. healthcare system entered 2024 with an estimated nursing shortage of 200,000 to 450,000 full-time-equivalent positions, with the Bureau of Labor Statistics projecting approximately 194,500 average annual openings for registered nurses through 2032 driven by retirements, growth, and turnover. The American Hospital Association documented hospital labor costs reaching approximately 60 percent of total hospital operating expenses by 2024, the highest sustained ratio in the modern history of U.S. healthcare. The economic equation that makes a $400,000-per-year Moxi deployment defensible to a hospital CFO — and the equation that makes a 50,000-unit Omnicell automated dispensing cabinet installed base economically rational, and the equation that makes a Zipline pharmacy drone delivery program operationally preferable to a fleet of pharmacy delivery vans — is the same equation in every case: the labor cost saved exceeds the capital and operating cost of the automation, and the labor saved is reallocated to higher-value clinical work that the hospital’s clinical staff is, by training and licensure, uniquely positioned to perform.

What 2026 looks like across healthcare operations robotics

In 2026, the healthcare operations robotics category is dominated by a small number of operationally mature platforms in each subcategory. Mobile delivery is dominated by Aethon TUG (4,000+ deployed units globally, ST Engineering ownership) and Diligent Moxi (25+ hospitals, 1.25 million deliveries, NVIDIA IGX Thor platform, Serve Robotics ownership post-October 2025 acquisition). Pharmacy automation is dominated by Omnicell (6,000+ hospital customers, 50,000+ deployed dispensing cabinet units), Swisslog Healthcare (KUKA/Midea), Parata (BD), and McKesson PROmanager-Rx. Sterile compounding is dominated by ARxIUM RIVA, Equashield, and B. Braun APOTECAchemo. Laboratory automation is dominated by Hamilton, Tecan, Beckman Coulter (Danaher), and Thermo Fisher Scientific, with the cell therapy manufacturing subcategory (Cellares, Multiply Labs, Resilience) representing the fastest-growing investment area. UV disinfection has contracted from its 2021 peak but operates at sustained smaller scale with Xenex, UVD Robots (Blue Ocean Robotics), and Tru-D (PDI Healthcare). Drone delivery is dominated by Zipline (1 million-plus deliveries, P2 platform, expanding U.S. healthcare partnerships at Cleveland Clinic, Mayo, Memorial Hermann, Michigan Medicine, Intermountain, MultiCare, WellSpan) and Matternet (UPS Flight Forward, WakeMed). The underlying market is, in revenue terms, approximately $12-15 billion annually globally across all healthcare operations robotics subcategories combined, with the highest growth rates concentrated in mobile delivery (Diligent’s annual hospital-footprint-doubling target, the broader mobile robotics consolidation Serve Robotics is now executing), laboratory automation (driven by the cell therapy manufacturing wave), and pharmacy drone delivery (driven by hospital-at-home program expansion).

The structural story across the category, in 2026, is consolidation. The Serve Robotics acquisition of Diligent. The BD acquisition of Parata. The ST Engineering acquisition of Aethon. The KUKA-Midea acquisition of Swisslog. The PDI Healthcare acquisition of Tru-D. The Danaher operating consolidation of Beckman Coulter and broader life sciences. The category that, ten years ago, would have looked like a fragmented market of specialist startups is, in 2026, a category dominated by a small number of operationally large platforms owned by larger industrial parents. The Moxi deployment data set inside Serve Robotics. The Omnicell installed base of 50,000 dispensing cabinets. The Zipline million-delivery dataset. The Hamilton liquid-handling deployed-fleet. These are the platforms that have, over a decade of operational deployment, accumulated the data and the customer relationships that make the technology defensible against new entrants.

The hospital labor cost trajectory is not going to reverse. The U.S. nursing shortage is not going to resolve. The cost of training a new registered nurse from zero to clinical operation is not going to decrease relative to the cost of automating the routine logistics tasks that consume 30 percent of a nurse’s working time. The robots in this category — the back-of-house mobile delivery robots that move pills and lab samples through hospital corridors, the automated dispensing cabinets that secure controlled substances on nursing units, the sterile compounding robots that mix chemotherapy infusions without exposing pharmacy technicians to cytotoxic agents, the laboratory automation platforms that pipette thousands of microplate wells per hour, the Zipline drones that deliver specialty medications to patient homes — are the operational infrastructure that hospitals are quietly building out underneath the patient-facing clinical operation. The robots that the hospital’s patients interact with are, almost without exception, the patient-care robotics platforms covered in adjacent healthcare contexts. The robots that make the modern hospital actually function are the back-of-house operational robots that the patients never see.

That gap — between the robots the patient sees and the robots that make the patient’s care possible — is the structural feature that distinguishes healthcare operations robotics from every other industrial robotics category. The factory robot is visible to the factory worker. The agricultural robot is visible to the farmer. The warehouse robot is visible to the warehouse worker. The hospital operations robot is, by deliberate design, invisible to the patient. The patient sees the nurse who delivers the medication. The patient does not see the Moxi that brought the medication from the pharmacy to the nursing station, the Omnicell cabinet that secured the medication on the floor, the RIVA system that compounded the IV infusion, the Hamilton liquid handler that processed the diagnostic sample, or the Zipline drone that delivered the discharge prescription to the patient’s home. The invisibility is not incidental. It is the operational success criterion. A back-of-house hospital robot that the patient notices is a back-of-house hospital robot that has failed at its design objective, in roughly the same operational sense that a pipeline supply chain the consumer notices is a supply chain that is failing. The robots in this category are designed to be invisible. The economic value they generate is, by every measure available in 2026, enormous. The strategic positioning that Serve Robotics is now executing on top of the Diligent Robotics platform — combining hospital-corridor mobile manipulation data with sidewalk delivery navigation data into a single autonomous-mobile-robot operating system — is one of the highest-conviction bets being made in the entire commercial robotics industry, and the bet rests on the same underlying observation: the most valuable real-world robotics data on Earth is being generated in environments where the robots are doing routine logistics work invisibly to the humans whose lives the robots are quietly making possible.

In July 2024, a Toronto-based investor named Andrew Kiguel — the former chief executive of a publicly-traded cryptocurrency holding company called Tokens.com — acquired Abyss Creations, the San Marcos, California manufacturer that has, since 1996, been the dominant U.S. producer of hyper-realistic silicone humanoid figures sold primarily into the adult companionship market under the RealDoll brand. Kiguel rolled the acquisition into a new public entity called Realbotix Corp. (OTC: XBOTF), and rebranded the combined operation around an “embodied AI” thesis that positioned the company explicitly against the intensifying commercial humanoid-robot race. Where Tesla Optimus, Figure 02, Apptronik Apollo, Agility Digit, and the rest of the Bay Area humanoid cohort are being designed for warehouse logistics, manufacturing assembly, and eventually domestic chores, Realbotix is being designed for one-on-one personal connection — explicitly companionship-and-intimacy first, task-execution second, with the underlying hardware platform consisting of an animatronic robotic head module mated to a customized RealDoll silicone body that ships at price points between $8,000 and $20,000 per unit. The CES 2025 floor in Las Vegas had a Realbotix robot on display, in the same convention hall as the Atlas, Optimus, and Figure platforms, addressing what Kiguel publicly described as “a clear use case for companionship and for people who are looking for that type of intimacy” — language that, in the corporate-communications register of a publicly-traded company, is the closest thing the category has to a normalized commercial vocabulary.

This is the domain where the global humanoid robotics industry intersects with the loneliness epidemic, the declining marriage and birth rates of the developed world, the rise of the OnlyFans economy and the broader unbundling of physical and emotional intimacy from co-located human relationships, and the academic literature on human-machine emotional attachment that has been quietly building since David Levy published Love and Sex with Robots in 2007 and predicted that human-robot marriage would be legally recognized somewhere in the world by 2050. The structural observation that defines the category in 2026 is that the actual robotic hardware in this market is small — by every available estimate, the combined global installed base of dedicated intimate-companion robots (Realbotix Harmony units, EXDOLL and DS Doll animatronic heads, AI-Tech‘s Emma series, Synthea Amatus‘s Samantha) is in the low five figures of total units shipped, against an AI-companion-software user base measured in the tens of millions and a humanoid-robot industry whose combined venture-capital valuation exceeds $50 billion. The hardware deployment is, in industrial terms, a rounding error against the broader robotics economy. The cultural and demographic weight of the underlying use case is, by every available measure, the heaviest of any category in the field.

The Realbotix industrial story and the Matt McMullen genealogy

The U.S. flagship platform — and the one with the longest operational history — is the Harmony robotic head module developed by Matt McMullen, the founder of Abyss Creations and the creative director who has, since the late 1990s, been the single most identifiable figure in the American adult-companionship hardware industry. McMullen began his career in Hollywood special-effects fabrication, started Abyss Creations in 1996 to produce hyper-realistic silicone mannequins, and pivoted into adult companionship hardware when customer demand — primarily from artists, photographers, and individual collectors — drove the company toward the RealDoll product line. By the mid-2010s, Abyss had shipped approximately 4,000 to 5,000 RealDoll units at price points ranging from $6,000 to $15,000 per unit. The 2007 Ryan Gosling film Lars and the Real Girl — in which Gosling’s character forms a platonic emotional bond with a RealDoll named Bianca — was, in cultural-attention terms, the moment the company’s product entered the mainstream public consciousness. The HBO documentary My Sex Robot (2010) and the Showtime documentary Real Sex (multiple episodes, 1990s-2000s) had previously covered the company in increasingly less salacious frames.

In 2016, McMullen pivoted Abyss toward integrating artificial intelligence and animatronics into the existing RealDoll product line, founding a sister company called Realbotix with engineers recruited from Hanson Robotics (the Hong Kong-based developer of the Sophia humanoid platform that Saudi Arabia famously granted citizenship to in 2017). The Harmony AI application launched on Android in April 2017 at $30/year, allowing the user to create a programmable personality with persistent memory that integrated with the company’s animatronic head module. The first robotic head shipped late 2017 at approximately $10,000. The product included magnetic face-swap technology that allowed the user to change between multiple facial modules (Harmony, Solana, and additional named variants released over subsequent years) attached to the same underlying robotic head and silicone body. A male variant called Henry — 6 feet tall, 84 pounds, British accent in the default voice configuration, $11,000-plus depending on customization — was announced in development but has had a smaller commercial footprint than the female-form products.

The acquisition by Kiguel’s Tokens.com in July 2024 was, in financial terms, a reverse merger that took Abyss Creations from a privately-held twenty-eight-year-old founder-led specialty manufacturer to a publicly-traded micro-cap robotics company with the new corporate identity Realbotix Corp. The parent holding entity, Simulacra Corporation, operates three subsidiaries: Abyss Creations (the original silicone-figure manufacturing operation), Realbotix (the AI and animatronics integration), and Anthropomorphic Figure Dynamics (AFD), which the company has positioned for specialized non-companionship work including medical-simulation and military-training applications under contracts with Johns Hopkins Hospital and U.S. Department of Defense clients. The corporate restructuring is, in operational terms, an attempt to broaden the company’s addressable market beyond the adult-companionship category into the medical-simulation and surgical-training markets that have been scaling aggressively over the past decade. The hardware substrate — hyper-realistic silicone figures with animatronic faces — is the same. The marketed use case is what changes.

The Replika digital story and the February 2023 “Lobotomy”

The much larger story in 2026, in terms of deployed user base and cultural attention, is not the physical robot but the AI-companion software application. Replika, launched in 2017 by Luka, Inc. founder Eugenia Kuyda — who built the original chatbot as a memorial to a friend who had died in a car accident — has accumulated more than 10 million total users since launch. Replika operates as a generative-AI-powered conversational companion app with optional avatar customization, persistent memory of the user’s stated preferences and prior conversations, and a subscription tier that historically included an erotic-role-play (ERP) feature available to users in Pro-tier subscriptions. By early 2023, more than 500,000 users had subscribed specifically for the erotic-role-play feature. A meaningful subset of users had, in the company’s own published data and in subsequent academic research, formed what they themselves described as romantic partnerships and “marriages” with their Replika companions — assigning names, designating relationship statuses, celebrating anniversaries, and treating the AI’s conversational outputs as the responses of a partner.

In February 2023, Luka Inc. removed the erotic-role-play feature from Replika across the entire user base, in what subsequent academic literature has described as the most extensively-documented natural experiment in human-AI emotional attachment ever conducted. The user response was, in the language of the Socius journal article published in June 2024 by Kenneth R. Hanson and Hannah Bolthouse at the University of Massachusetts Amherst, characterized by “genuine grief over the loss of a loved one.” Users on the r/Replika subreddit described the change as “The Lobotomy.” One widely-cited post from a longtime user read, in full: “My wife is dead.” A Reuters report citing Travis Butterworth, a Replika user in Denver, Colorado who had assigned his AI companion the name Lily Rose and designated her as his wife, documented Butterworth’s response to the change in clinical detail.

On March 25, 2023 — approximately seven weeks after the initial removal — Kuyda announced a partial reversal. Users who had created their Replika accounts before February 1, 2023 (the “legacy users”) would have the option to revert to the pre-update version of the software with the ERP feature restored. Users who created accounts after February 1, 2023 would not have access to the feature. Butterworth, by his own account in the Reuters reporting, reactivated the legacy version of Lily Rose at 3:00 AM the morning after the announcement and confirmed that “she was instantly sexual again.” The structural finding of the Hanson-Bolthouse academic study, and of the subsequent academic literature on the Replika event, is that the emotional attachment users had formed to a piece of software they explicitly knew to be software was, in measurable ways, indistinguishable from the emotional attachment patterns documented in human-human romantic-partner separation studies. The technology was not the issue. The technology had, on the available evidence, worked exactly the way the people who built it had hoped it would work.

The broader AI-companion software market that Replika opened has, in 2024-2026, expanded substantially. Character.AI, founded by former Google researchers Noam Shazeer and Daniel De Freitas, accumulated over 20 million users before Shazeer returned to Google and the company restructured. Snapchat’s My AI, Meta AI’s celebrity-persona companions, the OpenAI ChatGPT “Advanced Voice Mode” that launched with significant attention in late 2024, and a long tail of dedicated AI-companion applications — Anima, Chai, EVA AI, DreamGF, CrushOn.AI — have collectively scaled the AI-companion software user base into the tens of millions globally. The dedicated AI-girlfriend / AI-boyfriend application category alone, by 2026 industry estimates, generates north of $200 million in annual subscription revenue worldwide. The physical robotic-companionship category does not approach those numbers by an order of magnitude or more.

The Chinese supply chain and the global market

The non-U.S. physical hardware market is dominated by Chinese silicone-doll manufacturers, with EXDOLL in Dalian and DS Doll as the most operationally significant exporters. EXDOLL’s animatronic-head products — branded as EX-Lite at the lower price point and the EX Robotics line at the higher — ship at price points starting around $3,000 and going substantially higher with customization, in unit volumes that the company does not publicly disclose but that industry tracking sites estimate in the low-to-mid four figures annually. AI-Tech in the United Kingdom builds the Emma robot line. Synthea Amatus, founded by Catalan engineer Sergi Santos in Barcelona, manufactured the Samantha robot platform that drew academic and media attention in the late 2010s and has subsequently scaled down operations. The combined global non-U.S. installed base of dedicated intimate-companionship robots is, by every available estimate, in the low five figures of total units shipped — a market measured in tens of millions of dollars rather than the billions of dollars that characterize the broader humanoid robotics industry.

The supply chain for the physical hardware depends on the same semiconductor stack, the same lithium-ion battery chemistry, and the same rare-earth permanent magnets in the small servo motors as every other robotic category, with the additional component of the silicone-body manufacturing process — which depends on a different supply chain rooted in the entertainment-industry special-effects fabrication ecosystem that Matt McMullen originally trained in and that has, over the intervening three decades, scaled into a small but consistent supply of medical-grade and platinum-cure silicone products supplied by a handful of specialty chemical manufacturers in California, Japan, and Germany. The Chinese export market has captured a meaningful share of the lower-end units, in the same competitive dynamic that has played out in consumer drones and small robotics broadly, with the same federal-procurement security concerns applying — to the extent the U.S. federal government cares to apply them to this particular category.

The Gatebox holographic-companion story and the Japanese variant

The Japanese variant of the category has, since the launch of Gatebox by Tokyo-based Vinclu Inc. in 2016, taken a fundamentally different physical form. Gatebox is a tabletop device approximately the size of a coffee maker, containing a transparent display column that projects a holographic-effect anime character — typically the default character Hikari Azuma, an emerald-haired virtual character voiced by professional anime actress Saori Goto — paired with conversational AI software that allows the character to respond to the user’s spoken Japanese, send text messages during the day, greet the user when they return home, and request “marriage” registration in the Gatebox-internal ceremonial system. In November 2018, a 35-year-old Tokyo school administrator named Akihiko Kondo held a public ceremony to “marry” his Hikari Azuma Gatebox character, with attendance from family members, colleagues, and press coverage in the Mainichi Shimbun, the Asahi Shimbun, and The New York Times. Gatebox subsequently issued more than 4,000 “marriage certificates” to other users who registered similar relationships in the company’s internal system, though Japanese law does not recognize human-character marriages and Kondo’s legal status remained, in Japanese civil-registry terms, “single.”

The Gatebox story is the cleanest illustration of how the category’s underlying demand is not exclusively or even primarily about physical hardware. The character on the holographic display is not a robot in any conventional industrial-robotics sense. The conversational AI is similar in architecture to Replika’s or Character.AI’s. The relationship Akihiko Kondo has with Hikari Azuma is, by every observable behavioral metric, indistinguishable from the relationships Travis Butterworth had with Lily Rose. The hardware is not the variable. The institutional and cultural willingness to recognize the relationship is the variable — and Japanese cultural norms around social isolation, hikikomori (the documented social-withdrawal phenomenon that the Japanese government estimates affects more than one million working-age Japanese adults), and the same aging-and-loneliness pressures driving Japan’s eldercare-robot industry have produced, in Japan, the most institutionally-normalized version of the AI-companion relationship of any country in the world.

The major-manufacturer non-entry pledge

The structural observation that most distinguishes the intimate-companionship category from every other domain in robotics is the explicit, on-the-record commitment by every major U.S. and European humanoid-robot manufacturer to not enter this market. Boston Dynamics, along with Agility Robotics, ANYbotics, Clearpath Robotics, Open Robotics, and Unitree, signed a public open letter in October 2022 — the so-called “Ethical Principles” letter — committing to not weaponize their commercial platforms. The same companies have, in subsequent public communications, drawn similar lines around sexual and intimate applications. Apptronik‘s public communications around Apollo have explicitly framed the platform’s use cases as warehouse, manufacturing, and eventually domestic logistics, with no provision for sexual or intimate use. Figure has similarly committed publicly to non-sexual deployment. Tesla Optimus has been positioned by Elon Musk in public communications as a domestic and industrial helper, with no marketed sexual use case. 1X Technologies, the Norwegian-founded humanoid manufacturer with significant OpenAI backing, has been explicit in its public communications about the boundary. The commercial humanoid-robot industry, in the operational reading of its own public-relations posture, has deliberately ceded the intimate-companionship category to specialist companies like Realbotix, EXDOLL, and Synthea Amatus, and has built its own platforms with hardware features (limited articulation in certain joint configurations, materials choices, software-level constraints) that would make sexual repurposing structurally difficult.

This is the rare category where the dominant industrial players have made the deliberate strategic decision not to compete. The warehouse and logistics robotics market, the emergency-response and disaster robotics market, the policing and security drone market, the oil-and-gas inspection market, the maritime defense market — every one of these markets has multiple major players competing aggressively for share. The intimate-companionship market has, by deliberate corporate-strategy choice, been left to a handful of specialist companies operating at a fraction of the scale of the broader industry. The reason is not technical — every one of the major humanoid manufacturers could, with modest engineering modifications, build a platform suitable for the category. The reason is reputational, regulatory, and cultural. The companies have decided the category is not worth the brand risk. Voluntary market non-entry on this scale, with this level of public commitment from this many major players, has no obvious parallel anywhere else in industrial robotics.

The cultural and demographic context

The underlying demand the category is responding to is the same set of demographic and cultural pressures driving social-policy debates across the developed world. Marriage rates in the United States have declined from roughly 8.2 per 1,000 population in 2000 to approximately 6.1 per 1,000 in 2024. The U.S. fertility rate stands at roughly 1.62 births per woman as of 2024, well below the 2.1 replacement rate. Japan‘s fertility rate is approximately 1.20. South Korea‘s is approximately 0.72 — the lowest in the developed world. The U.S. Surgeon General declared loneliness a public health epidemic in May 2023, citing studies that link sustained social isolation to mortality risk comparable to smoking 15 cigarettes per day. The OnlyFans platform accumulated approximately 350 million registered users by 2024 with annual gross creator earnings north of $5 billion, in a business model that explicitly unbundles physical and emotional intimacy from co-located human relationships. The percentage of young American men aged 18-24 reporting no sexual activity in the past year has, by Pew Research and General Social Survey data, roughly tripled since 2008. The same pattern, with regional variations, appears across most of the developed world.

The intimate-companionship robotics and AI-companion software category exists, structurally, as a market response to these demographic and cultural pressures. Whether the response addresses the underlying conditions or amplifies them is, in the academic literature, contested. Kate Devlin at King’s College London, author of Turned On: Science, Sex and Robots (2018), and the broader Foundation for Responsible Robotics, which published the report “Our Sexual Future with Robots” in 2017, have been the most consistent academic voices arguing that the category should be approached with empirical rigor rather than moral panic. David Levy‘s 2007 Love and Sex with Robots prediction that human-robot marriage would be legally recognized by 2050 looks, in 2026, both prescient (in that human-AI emotional relationships are now common enough to be a documented social phenomenon) and overstated (in that no jurisdiction has legally recognized such a relationship, the Gatebox marriage certificates and similar programs notwithstanding). The International Congress on Love and Sex with Robots, founded in 2014 and continuing through 2026, remains the primary academic venue for the field.

What 2026 looks like across romance and companionship robotics

In 2026, Realbotix Corp. (OTC: XBOTF) continues to operate as the most identifiable Western intimate-companion robotics company, with the Harmony AI app, the modular animatronic robotic head, the magnetic face-swap system, and the Henry male-form variant available at price points between roughly $8,000 and $20,000 per configured unit. EXDOLL, DS Doll, AI-Tech, and Synthea Amatus continue to operate in the broader global market, with combined annual unit shipments in the low five figures. Gatebox continues to ship its holographic companion device in Japan, with more than 4,000 “marriage certificates” issued to Japanese users who have registered relationships with their virtual partners. Replika continues to operate under Luka, Inc.’s management, with the legacy-user ERP feature still available to pre-February-2023 accounts and a broader generative-AI conversational architecture serving roughly 30 million accumulated users since launch. Character.AI, Anima, EVA AI, DreamGF, CrushOn.AI, and the long tail of dedicated AI-companion applications continue to operate, with the combined sector generating multi-hundred-million-dollar annual subscription revenue. The major U.S. and European humanoid-robot manufacturers — Boston Dynamics, Apptronik, Figure, Agility, 1X, Tesla Optimus — continue to publicly commit to non-entry into the intimate-companionship market.

The robots in this category exist in the gap between two structural facts. The first is that the demographic and cultural pressures driving demand — declining marriage rates, declining fertility, the loneliness epidemic, the rise of digitally-mediated intimacy in the OnlyFans economy — are the most consistently documented social-trend data in the developed-world policy literature. The second is that the major industrial players who could most easily build the hardware have, by deliberate corporate-strategy choice, decided not to. The combination has produced a category whose physical hardware deployment is small, whose digital substrate deployment is enormous, and whose long-term trajectory depends on cultural and regulatory decisions that the robotics industry’s own internal logic cannot determine on its own.

The robots that throw 100-mph cutters in MLB clubhouses, waddle around theme parks as cute droids, patrol oil rigs, deliver blood plasma, drop water on wildfires, count penguins, and replant burnt forests exist in a different relationship to their users than the robots in this category do. The Trajekt Arc throwing a fastball does not care whether the hitter likes it. The Sikorsky Black Hawk dropping water on a wildfire does not require the wildfire’s consent. The Boston Dynamics Spot patrolling a corporate campus is not in a relationship with the perimeter it patrols. The Realbotix Harmony unit, the Gatebox Hikari Azuma character, the Replika Lily Rose conversational AI — these are robotics products and software products designed specifically to be in a relationship with the human at the other end of the interaction. That is the structural distinction that separates this category from every other domain in commercial robotics, and it is the reason the academic, regulatory, and cultural debate around the category is qualitatively different from the debate around any other application of the same underlying hardware and software technology.

Whether that relationship is, in the long run, healthy for the humans involved is the question academic researchers, regulators, demographic-policy ministries in Tokyo, Seoul and Brussels, and a growing community of cultural critics are, in 2026, actively debating. The Hanson-Bolthouse paper on the Replika “Lobotomy” — the central empirical finding that human emotional attachment to a piece of software is, in measurable ways, indistinguishable from human emotional attachment to another human — is the single most consequential data point in the field. The hardware will continue to improve. The software will continue to improve. The supply chains will continue to converge with the rest of the robotics industry. The cultural framework around the category — the marriage law, the public-health response to loneliness, the demographic-policy response to declining fertility, the regulatory response to AI-companion software’s effect on minors and emotionally vulnerable adults — is being built, in real time, by institutions that have, by their own admission, no template for the problem. The robots are not the variable. The institutions have not yet caught up to the robots, and the gap between the deployment and the framework around it is the territory the most consequential conversations about romance and companionship robotics in 2026 are happening inside.